Permanent protection of PLG scaffold transplanted allogeneic islet grafts in diabetic mice treated with ECDI-fixed donor splenocyte infusions

Biomaterials

Volumn 32, Issue 20, 2011, Pages 4517-4524

  Kheradmand, Taba ^a   Wang, Shusen ^a   Gibly, Romie F ^b   Zhang, Xiaomin ^a   Holland, Samantha ^b   Tasch, James ^a   Graham, Jack G ^b   Kaufman, Dixon B ^a   Miller, Stephen D ^a   Shea, Lonnie D ^b   Luo, Xunrong ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Northwestern University   (United States)

Author keywords

Allogeneic cell; Islet; Poly(lactide co glycolide) (PLG); Scaffold; Tolerance; Transplantation

Indexed keywords

ALLOGENEIC CELLS; ISLET; POLY LACTIDE-CO-GLYCOLIDE; TOLERANCE; TRANSPLANTATION;

SCAFFOLDS (BIOLOGY);

GLUCOSE; POLYGLACTIN;

ALLOTRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; EPIDIDYMIS FAT; GLUCOSE BLOOD LEVEL; GRAFT REJECTION; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; MALE; MOUSE; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; SPLEEN CELL;

ANIMALS; BIOCOMPATIBLE MATERIALS; CARBODIIMIDES; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; HUMANS; IMMUNE TOLERANCE; ISLETS OF LANGERHANS TRANSPLANTATION; MALE; MATERIALS TESTING; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; POLYGLACTIN 910; SPLEEN; TISSUE SCAFFOLDS; TRANSPLANTATION, HOMOLOGOUS;

MUS;

EID: 79955522742     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.03.009     Document Type: Article

References (38)

1. Robertson R.P. Islet transplantation a decade later and strategies for filling a half-full glass. Diabetes 2010, 59(6):1285-1291.
2. Luo X., Herold K.C., Miller S.D. Immunotherapy of type 1 diabetes: where are we and where should we be going?. Immunity 2010, 32(4):488-499.
3. Bennet W., Groth C.G., Larsson R., Nilsson B., Korsgren O. Isolated human islets trigger an instant blood mediated inflammatory reaction: implications for intraportal islet transplantation as a treatment for patients with type 1 diabetes. Ups J Med Sci 2000, 105(2):125-133.
4. Ozmen L., Ekdahl K.N., Elgue G., Larsson R., Korsgren O., Nilsson B. Inhibition of thrombin abrogates the instant blood-mediated inflammatory reaction triggered by isolated human islets: possible application of the thrombin inhibitor melagatran in clinical islet transplantation. Diabetes 2002, 51(6):1779-1784.
5. Ryan E.A., Paty B.W., Senior P.A., Bigam D., Alfadhli E., Kneteman N.M., et al. Five-year follow-up after clinical islet transplantation. Diabetes 2005, 54(7):2060-2069.
6. Shapiro A.M., Ricordi C., Hering B.J., Auchincloss H., Lindblad R., Robertson R.P., et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med 2006, 355(13):1318-1330.
7. Huebsch N., Mooney D.J. Inspiration and application in the evolution of biomaterials. Nature 2009, 462(7272):426-432.
8. Blomeier H., Zhang X., Rives C., Brissova M., Hughes E., Baker M., et al. Polymer scaffolds as synthetic microenvironments for extrahepatic islet transplantation. Transplantation 2006, 82(4):452-459.
9. Salvay D.M., Rives C.B., Zhang X., Chen F., Kaufman D.B., Lowe W.L., et al. Extracellular matrix protein-coated scaffolds promote the reversal of diabetes after extrahepatic islet transplantation. Transplantation 2008, 85(10):1456-1464.
10. Gutierrez-Dalmau A., Campistol J.M. Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review. Drugs 2007, 67(8):1167-1198.
11. Nir T., Melton D.A., Dor Y. Recovery from diabetes in mice by beta cell regeneration. J Clin Invest 2007, 117(9):2553-2561.
12. Luo X., Pothoven K.L., McCarthy D., DeGutes M., Martin A., Getts D.R., et al. ECDI-fixed allogeneic splenocytes induce donor-specific tolerance for long-term survival of islet transplants via two distinct mechanisms. Proc Natl Acad Sci U S A 2008, 105(38):14527-14532.
13. Jang J.H., Rives C.B., Shea L.D. Plasmid delivery in vivo from porous tissue-engineering scaffolds: transgene expression and cellular transfection. Mol Ther 2005, 12(3):475-483. [Article].
14. Rives C.B., Rieux des A., Zelivyanskaya M., Stock S.R., Lowe W.L., Shea L.D. Layered PLG scaffolds for in vivo plasmid delivery. Biomaterials 2009, 30(3):394-401.
15. Dufrane D., van Steenberghe M., Guiot Y., Goebbels R.M., Saliez A., Gianello P. Streptozotocin-induced diabetes in large animals (pigs/primates): role of GLUT2 transporter and beta-cell plasticity. Transplantation 2006, 81(1):36-45.
16. Goto M., Groth C.G., Nilsson B., Korsgren O. Intraportal pig islet xenotransplantation into athymic mice as an in vivo model for the study of the instant blood-mediated inflammatory reaction. Xenotransplantation 2004, 11(2):195-202.
17. Fontenot J.D., Rasmussen J.P., Gavin M.A., Rudensky A.Y. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 2005, 6(11):1142-1151.
18. Wood K.J., Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003, 3(3):199-210.
19. Shevach E.M. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 2009, 30(5):636-645.
20. Narang A.S., Mahato R.I. Biological and biomaterial approaches for improved islet transplantation. Pharmacol Rev 2006, 58(2):194-243.
21. Dufour J.M., Rajotte R.V., Zimmerman M., Rezania A., Kin T., Dixon D.E., et al. Development of an ectopic site for islet transplantation, using biodegradable scaffolds. Tissue Eng 2005, 11(9-10):1323-1331.
22. Chun S., Huang Y., Xie W.J., Hou Y., Huang R.P., Song Y.M., et al. Adhesive growth of pancreatic islet cells on a polyglycolic acid fibrous scaffold. Transplant Proc 2008, 40(5):1658-1663.
23. Berman D.M., O'Neil J.J., Coffey L.C., Chaffanjon P.C., Kenyon N.M., Ruiz P., et al. Long-term survival of nonhuman primate islets implanted in an omental pouch on a biodegradable scaffold. Am J Transplant 2009 Jan, 9(1):91-104.
24. Wang T., Chen L., Ahmed E., Ma L., Yin D., Zhou P., et al. Prevention of allograft tolerance by bacterial infection with Listeria monocytogenes. J Immunol 2008, 180(9):5991-5999.
25. Wang T., Ahmed E.B., Chen L., Xu J., Tao J., Wang C.R., et al. Infection with the intracellular bacterium, Listeria monocytogenes, overrides established tolerance in a mouse cardiac allograft model. Am J Transplant 2010, 10(7):1524-1533.
26. Contreras J.L., Eckstein C., Smyth C.A., Bilbao G., Vilatoba M., Ringland S.E., et al. Activated protein C preserves functional islet mass after intraportal transplantation: a novel link between endothelial cell activation, thrombosis, inflammation, and islet cell death. Diabetes 2004, 53(11):2804-2814.
27. Cui W., Wilson J.T., Wen J., Angsana J., Qu Z., Haller C.A., et al. Thrombomodulin improves early outcomes after intraportal islet transplantation. Am J Transplant 2009, 9(6):1308-1316.
28. Tokodai K., Goto M., Inagaki A., Nakanishi W., Ogawa N., Satoh K., et al. Attenuation of cross-talk between the complement and coagulation cascades by C5a blockade improves early outcomes after intraportal islet transplantation. Transplantation 2010, 90(12):1358-1365.
29. Rucker M., Laschke M.W., Junker D., Carvalho C., Schramm A., Mulhaupt R., et al. Angiogenic and inflammatory response to biodegradable scaffolds in dorsal skinfold chambers of mice. Biomaterials 2006, 27(29):5027-5038.
30. Thevenot P.T., Nair A.M., Shen J., Lotfi P., Ko C.Y., Tang L. The effect of incorporation of SDF-1alpha into PLGA scaffolds on stem cell recruitment and the inflammatory response. Biomaterials 2010, 31(14):3997-4008.
31. Lal G., Yin N., Xu J., Lin M., Schroppel S., Ding Y., et al. Distinct inflammatory signals have physiologically divergent effects on epigenetic regulation of foxp3 expression and treg function. Am J Transplant 2011, 11(2):203-214.
32. Hori S. Developmental plasticity of Foxp3+ regulatory T cells. Curr Opin Immunol 2010, 22(5):575-582.
33. Belkaid Y. Regulatory T cells and infection: a dangerous necessity. Nat Rev Immunol 2007, 7(11):875-888.
34. Nakamura K., Kitani A., Strober W. Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med 2001, 194(5):629-644.
35. Deepak P., Kumar S., Kishore D., Acharya A. IL-13 from Th2-type cells suppresses induction of antigen-specific Th1 immunity in a T-cell lymphoma. Int Immunol 2010, 22(1):53-63.
36. Davidson C., Verma N.D., Robinson C.M., Plain K.M., Tran G.T., Hodgkinson S.J., et al. IL-13 p.olongs allograft survival: association with inhibition of macrophage cytokine activation. Transpl Immunol 2007, 17(3):178-186.
37. Ke B., Shen X.D., Zhai Y., Gao F., Busuttil R.W., Volk H.D., et al. Heme oxygenase 1 mediates the immunomodulatory and antiapoptotic effects of interleukin 13 gene therapy in vivo and in vitro. Hum Gene Ther 2002, 13(15):1845-1857.
38. Highfill S.L., Rodriguez P.C., Zhou Q., Goetz C.A., Koehn B.H., Veenstra R., et al. Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13. Blood 2010, 116(25):5738-5747.